Q-omics provides the consensus-scored SPATA8 profile across patient tissues and cancer cell-line models. SPATA8 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPATA8 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, SPATA8 RNA expression shows 6,381 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUAD, and STAD as cancer lineages where SPATA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA8 survival associations across molecular data types. SPATA8 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA8 RNA expression–survival associations across cancer types. High SPATA8 expression shows unfavorable associations in ACC, KICH, BRCA, LGG and SKCM, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPATA8 RNA expression.
This table summarizes SPATA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA8 shows higher tumor expression in LUAD, LUSC, KIRC and THCA. The LUAD box plot shows higher SPATA8 RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p < 0.001).
This table shows molecular features associated with SPATA8 in patient tissues and cancer cell lines. In patient samples, SPATA8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
